Safety and Efficacy of Argatroban in the Management of Heparin-Induced Thrombocytopenia

Safety and Efficacy of Argatroban in the Management of Heparin-Induced Thrombocytopenia

Show other versions (1)

Heparin-induced thrombocytopenia (HIT) is a life-threatening adverse reaction to heparin therapy that is characterized by thrombocytopenia and an increased risk of venous and arterial thrombosis. According to guidelines, in patients with strongly suspected or confirmed HIT all sources of heparin hav...

Full description

Bibliographic Details
Main Authors: Bernd Saugel, Roland M. Schmid, Wolfgang Huber
Format: Article
Language:English
Published: SAGE Publishing 2011-01-01
Series:Clinical Medicine Insights: Blood Disorders
Online Access:https://doi.org/10.4137/CMBD.S5118
id doaj-0f29aa91abaf4fc9a63fe7242dbad7c7
record_format Article
spelling doaj-0f29aa91abaf4fc9a63fe7242dbad7c72020-11-25T03:25:09ZengSAGE PublishingClinical Medicine Insights: Blood Disorders1179-545X2011-01-01410.4137/CMBD.S5118Safety and Efficacy of Argatroban in the Management of Heparin-Induced ThrombocytopeniaBernd Saugel0Roland M. Schmid1Wolfgang Huber2II. Medizinische Klinik und Poliklinik. Klinikum rechts der Isar der Technischen Universität München, Ismaninger Strasse 22, D-81675 München, Germany.II. Medizinische Klinik und Poliklinik. Klinikum rechts der Isar der Technischen Universität München, Ismaninger Strasse 22, D-81675 München, Germany.II. Medizinische Klinik und Poliklinik. Klinikum rechts der Isar der Technischen Universität München, Ismaninger Strasse 22, D-81675 München, Germany.Heparin-induced thrombocytopenia (HIT) is a life-threatening adverse reaction to heparin therapy that is characterized by thrombocytopenia and an increased risk of venous and arterial thrombosis. According to guidelines, in patients with strongly suspected or confirmed HIT all sources of heparin have to be discontinued and an alternative, nonheparin anticoagulant for HIT treatment must immediately be started. For both the prophylaxis of thrombembolic events in HIT and the treatment of HIT with thrombosis the direct thrombin inhibitor argatroban is approved in the United States. The objective of this review is to describe the mechanism of action and the pharmacokinetic profile of argatroban, to characterize argatroban regarding its safety and therapeutic efficacy and to discuss its place in therapy in HIT.https://doi.org/10.4137/CMBD.S5118
collection DOAJ
language English
format Article
sources DOAJ
author Bernd Saugel
Roland M. Schmid
Wolfgang Huber
spellingShingle Bernd Saugel
Roland M. Schmid
Wolfgang Huber
Safety and Efficacy of Argatroban in the Management of Heparin-Induced Thrombocytopenia
Clinical Medicine Insights: Blood Disorders
author_facet Bernd Saugel
Roland M. Schmid
Wolfgang Huber
author_sort Bernd Saugel
title Safety and Efficacy of Argatroban in the Management of Heparin-Induced Thrombocytopenia
title_short Safety and Efficacy of Argatroban in the Management of Heparin-Induced Thrombocytopenia
title_full Safety and Efficacy of Argatroban in the Management of Heparin-Induced Thrombocytopenia
title_fullStr Safety and Efficacy of Argatroban in the Management of Heparin-Induced Thrombocytopenia
title_full_unstemmed Safety and Efficacy of Argatroban in the Management of Heparin-Induced Thrombocytopenia
title_sort safety and efficacy of argatroban in the management of heparin-induced thrombocytopenia
publisher SAGE Publishing
series Clinical Medicine Insights: Blood Disorders
issn 1179-545X
publishDate 2011-01-01
description Heparin-induced thrombocytopenia (HIT) is a life-threatening adverse reaction to heparin therapy that is characterized by thrombocytopenia and an increased risk of venous and arterial thrombosis. According to guidelines, in patients with strongly suspected or confirmed HIT all sources of heparin have to be discontinued and an alternative, nonheparin anticoagulant for HIT treatment must immediately be started. For both the prophylaxis of thrombembolic events in HIT and the treatment of HIT with thrombosis the direct thrombin inhibitor argatroban is approved in the United States. The objective of this review is to describe the mechanism of action and the pharmacokinetic profile of argatroban, to characterize argatroban regarding its safety and therapeutic efficacy and to discuss its place in therapy in HIT.
url https://doi.org/10.4137/CMBD.S5118
work_keys_str_mv AT berndsaugel safetyandefficacyofargatrobaninthemanagementofheparininducedthrombocytopenia
AT rolandmschmid safetyandefficacyofargatrobaninthemanagementofheparininducedthrombocytopenia
AT wolfganghuber safetyandefficacyofargatrobaninthemanagementofheparininducedthrombocytopenia
_version_ 1724598751339741184

Similar Items